Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-461 in Crohn's Disease
NCT00042055Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2002
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CP-461 in Crohn's disease, sponsored by Astellas Pharma. Primary endpoint: Improvement in symptoms of Crohn's disease at 8 weeks. Started Jul 2002; status: completed.
02
Drugs
CP-461
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00042055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042055.